- Dr. John D. Clemens of Seoul-based international organization cited by World Vaccine Congress Asia
SEOUL, Korea - Dr. John D. Clemens, Director-General of the International Vaccine Institute (IVI), was awarded “Vaccine Executive of the Year” by the World Vaccine Congress Asia at its Vaccine Industry Excellence (ViE) Asia 2010 Awards in Singapore recently.
The IVI, headquartered in Seoul, Korea, is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines for the world’s poorest people, especially children.
As the head of the IVI, Dr. Clemens was honored for his contributions and achievements in the vaccine field in the Asia region. “Dr. Clemens was recognized for exhibiting visionary leadership with an outstanding degree of commitment to disease prevention and control with vaccine research and development,” the World Vaccine Congress Asia noted on the award. IVI scientist Rodney Carbis received the award on Dr. Clemens’ behalf at the inaugural ViE awards ceremony on June 9, which brought together executives from leading global and Asian vaccine manufacturers.
The Vaccine Executive of the Year was selected through a poll with nominations solicited from more than 200,000 individuals from the vaccine and biotechnology industries. Three finalists were selected: Weidong Yin, CEO of the Chinese vaccine manufacturer Sinovac Biotech; Cyrus Poonawalla, Chairman of the Serum Institute of India, and Dr. Clemens. Dr. Clemens emerged as the winner in the second round of voting, which involved 10,000 voters.
“I am very honored to become the first winner of the Vaccine Executive of the Year Award,” said Dr. Clemens, who received in April this year’s Albert Sabin Gold Medal, one of the highest honors in vaccine research. “This is recognition by the Asian vaccine industry and community for the importance and success of the IVI’s effort to accelerate the development and introduction of new vaccines for populations in developing countries, including the IVI ’s development of the world’s first low-cost oral cholera vaccine that was licensed in India last year.”
The World Vaccine Congress is now in its 10th year and is regarded as one of the most important meetings for the vaccine industry. In 2007, World Vaccine Congress Asia was launched to support Asia’s burgeoning vaccine markets. Now in its fourth year, the World Vaccine Congress Asia is the largest gathering for vaccines in Asia.
About the World Vaccine Congress Asia
World Vaccine Congress Asia is the largest vaccine gathering in the region. Strategically co-located with the Asia Infectious Diseases Forum and World Influenza Congress, World Vaccine Congress Asia is a platform where major decision makers across the global vaccine industry meet. For more information, please visit: http://www.terrapinn.com/2010/wvcasia
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines for the world’s poorest people, especially children in developing countries. Established as an initiative of the United Nations Development Program in 1997, the IVI operates under a treaty signed by 40 countries and the World Health Organization. The IVI conducts research in 30 countries in Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, Japanese encephalitis, dengue fever, and more. For further information, please visit: www.ivi.int